Citations

Clear

163 citation(s) found for "Sharp, H L".

Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL
Ahmed, Nausheen , Nogueira Serodio, Alline , Villasboas, Jose Caetano , Sharp, John , Voorhees, Timothy J , Houshyar, Samin , Wallace, Danielle S , Wagner, Charlotte , Bock, Allison M , Brooks, Taylor R , Al Any, Haya, Rajab, Mohamed , Gupta, Supriya , Karmali, Reem , Trotier, Daniel C , Pophali, Priyanka , Ricker, Edd , Cherng, Hua-Jay J , Torka, Pallawi , Trabolsi, Asaad , Schatz, Jonathan H , Gupta, Arjun

Mayo Clinic

Blood Advances | October 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020899 | PMID 42962270 Get It

Chimeric antigen receptor T-cell (CAR-T) and CD20xCD3 bispecific antibody (BsAb) therapies are both effective for relapsed/refractory (R/R) follicular lymphoma (FL), but comparative real-world survival outcomes and time toxicity have not been characterized. We performed a multicenter retrospective study of 228 patients with R/R FL treated with standard-of-care CAR-T (n = 141) or BsAb (n = 87) across 17 U.S. academic centers in the third-line or later setting. Progression-free survival (PFS) and overall survival (OS) were stratified by 2 or ≥3 prior lines of therapy (LOT2 or LOT3+), including propensity matching. Time toxicity was measured by physical health care contact days. Median PFS was not reached (NR) with CAR-T and 581 days with BsAb in the LOT2 cohort (p < .0001), and was NR with CAR-T and 584 days with BsAb in the LOT3+ cohort (p = .0064). CAR-T recipients were younger (p < .0001) and had better performance status (p = .007) but were more refractory to prior LOT (p = .017). PFS advantages of CAR-T were independent of these differences. OS did not differ between treatment groups. CAR-T had significantly greater time toxicity over the first year, with higher mean contact days than BsAb in both the LOT2 (58 vs 44) and LOT3+ (69 vs 49) cohorts. In this large multicenter cohort of patients with R/R FL, CAR-T was associated with superior PFS but greater time toxicity compared with BsAb therapy. These findings provide real-world outcomes data and time toxicity benchmarks to support treatment sequencing decision-making in R/R FL.
Global Transcriptional Differences in Staphylococcus aureus Biofilm-Associated Genes in a brpR Mutant Compared to Wild-Type Strain
Dyce, Hailey, Johnson, Stephen , Sharp, Isabelle, Schwan, William R. , Schweiger, Paul , Johnson, Stephen , Schwan, William R , Patel, Robin

Mayo Clinic

Antibiotics | August 14, 2026 | Volume: 15 | Issue: 8 | Pages: 787

10.3390/antibiotics15080787 | PMID 42650712 Get It

Background: Staphylococcus aureus causes bloodstream and skin infections in humans. The prevalence of multidrug-resistant S. aureus strains means new antibiotics are needed. A novel antimicrobial drug named SK-03-92, a synthetic aromatic organic stilbenoid compound, kills S. aureus cells within 30 min, but an increase in both biofilm formation and persister cells occurs. SK-03-92 treatment downregulates transcription of the biofilm regulating protein regulator (brpR) gene and biofilm regulating protein sensor (brpS) gene in S. aureus. BrpR/BrpS system may be a LytTR regulatory system tied to biofilm formation, creation of persister cells, and late-stage competence in S. aureus. The aim of this study was to determine what biofilm, late-stage competence, and persister-associated genes were regulated in a brpR mutant compared to wild-type strains. Methods: In this study, involvement of BrpR in regulating other genes was assessed by comparing transcriptional changes in a brpR mutant strain to the S. aureus parent strain via RNA sequencing (RNA-Seq). Bioinformatic analysis was then performed on the RNA-Seq data to assess what biochemical pathways might be involved. Results: From these analyses, 440 genes were identified that had significant differences in transcript abundance when comparing the brpR mutant to wild-type strains. Quantitative reverse transcription polymerase chain reaction analysis confirmed bacA, icd, metE, and pdhA transcript levels were lower, whereas alr and mraY were higher in the brpR mutant versus wild-type strain. Furthermore, an enzymatic assay targeting NADH production from the pyruvate dehydrogenase complex showed lower levels in the mutant compared to wild-type strain. Conclusions: Overall, the study demonstrated several biosynthetic pathways tied to biofilm formation and late-stage competency may be regulated by BrpR and some potential leads for the mechanism of action of the SK-03-92 drug were uncovered.
Reimagining Bioethics in the Era of AI Agents
Stroud, Austin M. , Sharp, Richard R , Sharp, Richard R.

Mayo Clinic

The American Journal of Bioethics | August 3, 2026 | Volume: 26 | Issue: 8 | Pages: 3-5

10.1080/15265161.2026.2704452 | PMID 42545292 Get It

Defending the Ethical Permissibility of Laryngeal Transplantation
Lott, David G. , Ellertson, Marka , Grandjean, Danielle N. , Sj, Zacharias, Strome, Marshall, Beck, Annika T., Teven, Chad M., Zacharias, Stephanie R, Sharp, Richard R , Ellertson, Marka F. , Lott, David G , Zacharias, Stephanie R., Teven, Chad M. , Sharp, Richard R.

Mayo Clinic

The American Journal of Bioethics | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.1080/15265161.2026.2691944 | PMID 42377982 Get It

How We Do It: Antitragus Repair Through Single-Stage Transposition Flap
Ho, Johne, Newcomer, Jack, Carley, Sama K. , Ho, Jade Y, Newcomer, Jack

Mayo Clinic

Dermatologic Surgery | May 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dss.0000000000005198 | PMID 42201562 Get It

Reducing light sensitivity during and between migraine attacks: A prospective study investigating spectral tuning of white light
Fani, Mahya, Sharp, Nina, Schwedt, Todd J. , Schwedt, Todd J , Sharp, Nina

Mayo Clinic

Cephalalgia | April 15, 2026 | Volume: 46 | Issue: 4 | Pages: No page available

10.1177/03331024261439257 | PMID 41983992 Get It

Background Photophobia is experienced by most individuals with migraine, and it is frequently the most bothersome symptom other than headache. Light is not perceived uniformly; spectral composition and intensity influence discomfort and can exacerbate symptoms. While monochromatic green light shows therapeutic potential, it appears visually unnatural and is impractical for daily use. This study aimed to determine whether spectrally tailored white light, more visually acceptable in everyday environments, reduces light sensitivity among those with migraine. Methods Twenty adults (18–44 years) with episodic migraine completed two research sessions: one during an acute migraine attack and one between migraine attacks. Participants were exposed to four spectrally distinct white light conditions (red-, green-, cyan-, and blue-enriched) in a randomized order delivered at ten intensity levels (50–590 lux). After each exposure, visual discomfort was rated on a 0–10 scale. Pupil size was measured using a pupillometer. Repeated-measures ANOVAs examined the effects of light spectrum, intensity, and migraine state on visual discomfort and pupil response. Results Migraine attack status significantly increased visual discomfort ( F (1,19) = 25.84, p < .001, η 2 = .576). White light spectrum ( F (3,57) = 12.47, p < .001, η 2 = .396) and light intensity ( F (9171) = 124.30, p < .001, η 2 = .867) were associated with intensity of visual discomfort. Post-hoc analyses indicated that visual discomfort increased with increasing light intensity, especially at higher light intensities. Among all tested spectra, green-enriched white light resulted in the least visual discomfort; blue-, red-, and cyan-enriched white light produced significantly higher discomfort (all p < .001). Pupil size varied by spectrum ( F (3,57) = 14.13, p < .001, η 2 = .426), with green-enriched white light producing the largest pupil size. Conclusion Spectral composition, light intensity, and migraine state jointly influence both subjective and physiological responses to light. Across lighting spectra, lower light intensity was consistently associated with reduced visual discomfort, indicating greater visual comfort at lower intensities. These results identify green-enriched white light at lower intensities as a visually acceptable, migraine-conscious lighting option with potential for real-world application.
Inflammatory arthritis irAE may represent a unique autoimmune disease primarily driven by T cells but likely not autoantibodies
Zhu, Xingxing, Yu, Yue , Chen, S., Langenfeld, Hannah E., Li, Yanfeng , Wang, Panwen , McCabe, Chantal E. , Hanson, Andrew C. , Sharp, Brenna , Woltzen, Amber, Markovic, Svetomir N. , Davis, John M., Dong, H. C., Crowson, Cynthia S., Thanarajasingam, Uma , Zeng, Hu, Dong, Haidong , Davis, John M. , Zeng, Hu , Zhu, Xingxing , Li, Ying , Zhu, Xingxing , Chen, Shiju, McCabe, Chantal , Hanson, Andrew C , Sharp, Brenna E, Woltzen, Amber , Markovic, Svetomir , Davis, John M , Dong, Haidong , Crowson, CS , Thanarajasingam, Uma , Zeng, Hu , Li, Ying , Li, Ying, Crowson, Cynthia S.

Mayo Clinic

Science Advances | April 1, 2026 | Volume: 12 | Issue: 14 | Pages: No page available

10.1126/sciadv.aea4262 | PMID 41920990 Get It

The underlying immunopathogenesis of inflammatory arthritis (IA) immune-related adverse event (irAE) remains obscure. Unlike rheumatoid arthritis (RA), where autoantibodies and B cell dysfunction are central features, the contribution of humoral immunity to IA-irAE is unclear. Here, we performed immunophenotyping of peripheral blood from patients with IA-irAE and compared them with patients with seronegative RA, immune checkpoint inhibition–treated patients without irAE, and healthy controls. IA-irAE was marked with increased cytotoxic gene expression and metabolic activation in T cells and reduced CXCR3 and CCR6 expression in CD4 + T cells. Contrary to seronegative RA, patients with IA-irAE displayed no substantial elevation in autoantibody levels or atypical CD11c + CD21 − B cells. IA-irAE was further characterized by elevated levels of interleukin-6 (IL-6), IL-12, and type I interferon, which correlated with the T cell activation phenotypes. Together, our findings define IA-irAE as a disease with certain immunological features distinctive from RA, representing a potentially T cell–driven, autoantibody-independent autoimmunity. These results offer insights into immune tolerance breakdown and therapeutic targeting in irAEs.
Abstract B032: Drug and single-cell gene expression integration identifies heterogeneity-aware synergistic combinations for glioblastoma
Suter, Robert K. , Jermakowicz, Anna, Veeramachaneni, Rithvik, D'Antuono, Matthew, Zhang, L.G., Chowdary, Rishika , Kaeppeli, Simon , Sharp, Madison, Palwai, Pravallika, Stathias, Vasileios , Baker, Grace, Ruiz, Luz , Walters, Winston, Cepero, Maria, Reilly, Edward B. , Oleksijew, Anatol, Anderson, Mark G. , Williams, Sion Ll., Komotar, Ricardo J., Fuente, Macarena I. de la , Stein, Gregory , Wojcinski, Alexandre , Schürer, Stephan C. , Ayad, Nagi , Jermakowicz, Anna M. , D’Antuono, Matthew , Palwai, Pravallika, Cepero, Maria L., Burgenske, Danielle M. , Ivan, Michael E , Stein, Gregory, Kesari, Santosh , Sarkaria, Jann N. , Ayad, Nagi G.

Mayo Clinic

Cancer Research | March 23, 2026 | Volume: 86 | Issue: 6_Supplement | Pages: B032-B032

10.1158/1538-7445.brain26-b032 Get It

Abstract Glioblastoma (GBM) remains the most common and lethal adult malignant primary brain cancer with few treatment options. A significant issue hindering GBM therapeutic development is intratumor heterogeneity and plasticity. GBM tumors contain neoplastic cells within a fluid spectrum of diverse transcriptional states. Identifying effective therapeutics requires a platform that predicts the differential sensitivity and resistance of these states to various treatments. Here, we develop scFOCAL (Single-Cell Framework for -Omics Connectivity and Analysis via L1000), to quantify the cellular drug sensitivity and resistance landscape. Using single-cell RNA sequencing of newly diagnosed and recurrent GBM tumors, we identify compounds from the LINCS L1000 database with transcriptional response signatures selectively discordant with distinct GBM cell states, and leverage this capability to predict combination synergy. We validate the significance of these findings in vitro, ex vivo, and in vivo, and use the Olig2 inhibitor CT-179 as a reference drug to identify additional small molecules that would maximize the cell-drug discordance across the GBM transcriptional landscape. Our analysis leads to the combination of Olig2 inhibition with treatment with Depatux-M, of with which we demonstrate synergy in vivo. Our studies suggest that scFOCAL identifies cell states that are sensitive and resistant to targeted therapies in GBM using a measure of cell and drug connectivity, which can be applied to identify new synergistic combinations. Citation Format: Robert K. Suter, Anna M. Jermakowicz, Rithvik Veeramachaneni, Matthew D'Antuono, Longwei Zhang, Rishika Chowdary, Simon Kaeppeli, Madison Sharp, Pravallika Palwai, Vasileios Stathias, Grace Baker, Luz Ruiz, Winston Walters, Maria Cepero, Danielle Burgenske, Edward B. Reilly, Anatol Oleksijew, Mark G. Anderson, Sion Ll. Williams, Michael E. Ivan, Ricardo J. Komotar, Macarena I. De La Fuente, Gregory Stein, Alexandre Wojcinski, Santosh Kesari, Jann N. Sarkaria, Stephan C. Schürer, Nagi G. Ayad. Drug and single-cell gene expression integration identifies heterogeneity-aware synergistic combinations for glioblastoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Brain Cancer; 2026 Mar 23-25; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(6_Suppl):Abstract nr B032.
Ethical Considerations for AI-Enabled Voice Analysis: Features of an Emerging Bioethics Literature
Anzabi, Michele D. , Stroud, Austin M. , Sharp, Richard R , Sharp, Richard R.

Mayo Clinic

AJOB Empirical Bioethics | March 7, 2026 | Volume: 17 | Issue: 2 | Pages: 61-76

10.1080/23294515.2026.2632091 | PMID 41793391 Get It